Loading patent…
AssigneeImmunityBio, Inc.
InventorsHans G. Klingemann, Laurent H. Boissel, Nathan T. Schomer
Estimating the term…
Provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) a homing receptor, ii) Antigen Binding Protein (ABP) or Chimeric Antigen Recpetor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Further provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) IL-12 and/or TGF-beta trap, ii) an Antigen Binding Protein (ABP) or Chimeric Antigen Recpetor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Also provided are compositions and kits comprising the modified NK-92® cells, as well as methods of treating cancer using the modified cells.
A recombinantly modified natural killer (NK)-92 cell stably transfected with a nucleic acid:
A recombinantly modified NK92 cell stably transfected with a recombinant nucleic acid and expressing from the recombinant nucleic acid an anti-programmed cell death 1 ligand 1 (PD-L1) chimeric antigen receptor (CAR) having the amino acid sequence of SEQ ID NO:69, an Fc receptor, a CCR7 homing receptor, and a cytokine, wherein the anti PD-L1 CAR and the Fc receptor are expressed on a cell surface of the recombinantly modified NK92, and wherein the NK-92 cell has ATCC Deposit No. CRL-2407;
Dependencies are inferred from the claim text.